Analyzing the short-term effect of placebo therapy in pulmonary arterial hypertension: Potential implications for the design of future clinical trials

Chest

Volumn 132, Issue 3, 2007, Pages 764-772

  Helman Jr , Donald L ^a   Brown, Alexander W ^a   Jackson, Jeffrey L ^b   Shorr, Andrew F ^c  

^a EISENHOWER ARMY MEDICAL CENTER   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

6 min walk distance; Metaanalysis; Mortality; Outcome; Placebo; Pulmonary arterial hypertension; Pulmonary hemodynamics

Indexed keywords

PLACEBO;

CLINICAL TRIAL; HUMAN; META ANALYSIS; METHODOLOGY; PULMONARY HYPERTENSION; REVIEW; TIME; TREATMENT OUTCOME;

CLINICAL TRIALS; HUMANS; HYPERTENSION, PULMONARY; PLACEBOS; RESEARCH DESIGN; TIME FACTORS; TREATMENT OUTCOME;

EID: 35448987677     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.07-0236     Document Type: Article

References (60)

1. Rubin LJ. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126(suppl):7S-10S (Pubitemid 38932338)
2. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43(suppl):5S-12S (Pubitemid 38759712)
3. Fisher MR, Mathai SC, Champion HC, et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum 2006; 54:3043-3050 (Pubitemid 44497786)
4. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173:1023-1030
5. McLaughlin VV, Presberg KW, Doyle RL, et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126(suppl):78S-92S (Pubitemid 38932344)
6. Hyduk A, Croft JB, Ayala C, et al. Pulmonary hypertension surveillance: United States, 1980-2002. MMWR Morb Mortal Wkly Rep 2005; 54:1-28
7. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334:296-301 (Pubitemid 26033085)
8. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991; 115:343-349
9. Saunders J, Wainwright P. Risk, Helsinki 2000 and the use of placebo in medical research. Clin Med 2003; 3:435-439 (Pubitemid 37328460)
10. Miller FG, Shorr AF. Ethical assessment of industry-sponsored clinical trials: a case analysis. Chest 2002; 121:1337-1342 (Pubitemid 34280461)
11. Miller FG, Brody H. What makes placebo-controlled trials unethical? Am J Bioeth 2002; 2:3-9
12. Ballantyne A. HIV international clinical research: exploitation and risk. Bioethics 2005; 19:476-491 (Pubitemid 41527504)
13. Mudur G. Indian study sparks debate on the use of placebo in psychiatry trials [letter]. BMJ 2006; 332:566
14. Siegel JP. Equivalence and noninferiority trials. Am Heart J 2000; 139:S166-S170 (Pubitemid 30207813)
15. Gomberg-Maitland M, Frison L, Halperin JL. Active-control clinical trials to establish equivalence or noninferiority: meth- odological and statistical concepts linked to quality. Am Heart J 2003; 146:398-403 (Pubitemid 37083073)
16. Gomberg-Maitland M, Preston IR. Prostacyclin therapy for pulmonary arterial hypertension: new directions. Semin Respir Crit Care Med 2005; 26:394-401 (Pubitemid 41266496)
17. Peacock A, Naeije R, Galie N, et al. End points in pulmonary arterial hypertension: the way forward. Eur Respir J 2004; 23:947-953 (Pubitemid 38807372)
18. Hoeper MM, Oudiz RJ, Peacock A, et al. End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. J Am Coll Cardiol 2004; 43(suppl):48S-55S (Pubitemid 38759717)
19. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized controlled trials: is blinding necessary? Control Clin Trials 1996; 17:1-12 (Pubitemid 26120810)
20. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347:322-329 (Pubitemid 34815354)
21. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-188 (Pubitemid 17189972)
22. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:629-634 (Pubitemid 27387172)
23. Galbraith RF. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med 1988; 7:889-894
24. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000; 56:455-463 (Pubitemid 30422636)
25. Berkey CS, Hoaglin DC, Mosteller F, et al. A random effects regression model for meta-analysis. Stat Med 1995; 14:395-411
26. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial. Ann Intern Med 2000; 132:425-434 (Pubitemid 30149039)
27. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358:1119-1123 (Pubitemid 32971843)
28. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2002; 165:800-804 (Pubitemid 34229650)
29. Langleben D, Christman BW, Barst RJ, et al. Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension. Am Heart J 2002; 143:e4
30. Galie N, Humbert M, Vachiery JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002; 39:1496 -1502
31. Rubin LJ, Basesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903 (Pubitemid 34984638)
32. Barst RJ, McGoon MM, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41:2119-2125 (Pubitemid 36724255)
33. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 169:441-447 (Pubitemid 38187114)
34. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353:2148-2157 (Pubitemid 41653106)
35. Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin- A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006; 47:2049-2056
36. Galie N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double- blind, randomized, placebo-controlled study. Circulation 2006; 114:48-54 (Pubitemid 44305274)
37. Wilkins MR, Paul GA, Strange JW, et al. Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study. Am J Respir Crit Care Med 2005; 171: 1199-1201
38. Badesch DB, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126(suppl):35S-62S (Pubitemid 38932341)
39. Galie N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension: the task force on diagnosis and treatment of pulmonary arterial hypertension of the European Society of Cardiology. Eur Heart J 2004; 25:2243-2278
40. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension: comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000; 161:487-492 (Pubitemid 30129457)
41. Oudiz RJ, Barst RJ, Hansen JE, et al. Cardiopulmonary exercise testing and six-minute walk correlations in pulmonary arterial hypertension. Am J Cardiol 2006; 997:123-126 (Pubitemid 41828135)
42. Frost AE, Langleben D, Oudiz R, et al. The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect. Vascul Pharmacol 2005; 43:36-39 (Pubitemid 40828831)
43. Okada O, Tanabe N, Yasuda J, et al. Prediction of life expectancy in patients with primary pulmonary hypertension: a retrospective nationwide survey from 1980-1990. Intern Med 1999; 38:12-16
44. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40:780-788 (Pubitemid 34925627)
45. Rich S. The current treatment of pulmonary arterial hypertension: time to redefine success. Chest 2006; 130:1198-1202 (Pubitemid 44583753)
46. Fleming TR. Surrogate end points in cardiovascular disease trials. Am Heart J 2000; 139:S193-S196 (Pubitemid 30207818)
47. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin converting enzyme inhibitors or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002; 288:2981-2997
48. Rubinstein E, Cammarata S, Oliphant T, et al. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001; 32: 402-412 (Pubitemid 32173626)
49. Moeller A, Given M, Coyne TC. Comparison of placebocontrolled and open label trials in pulmonary arterial hypertension [abstract]. Am J Respir Crit Care Med 2005; 171: A201
50. Singh TP, Rohit M, Grover A, et al. A randomized, placebocontrolled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J 2006; 151:851.e1-e5
51. Voswinckel R, Enke B, Reichenberger F, et al. Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. J Am Coll Cardiol 2006; 48:1672-1681 (Pubitemid 44528194)
52. Humbert M, Barst RJ, Channick RN, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004; 24:353-359 (Pubitemid 39232254)
53. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006; 174:1257-1263 (Pubitemid 44924827)
54. Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006; 28:691-694 (Pubitemid 46331988)
55. Stewart LA, Tierney JF. To IPD or not to IPD? Advantages and disadvantages of systematic rewiews using individual patient data. Eval Health Prof 2002; 25:76-97 (Pubitemid 34157785)
56. Lyman GH, Kuderer NM. The strengths and limitations of meta-analyses based on aggregate data. BMC Med Res Methodol 2005; 5:14
57. Simmonds, Higgins JP, Stewart LA, et al. Meta-analysis of individual patient data from randomized trials: a review of methods used in practice. Clin Trials 2005; 2:209 -217
58. McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005; 25:244-249 (Pubitemid 40246523)
59. Sitbon O, Badesch DB, Channick RN, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1 year follow-up study. Chest 2003; 124:247-254 (Pubitemid 36851359)
60. Langleben D, Hirsch AM, Shalit E, et al. Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-a receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: a 1 year follow-up study. Chest 2004; 126:1377-1381 (Pubitemid 39391276)